Compare DOGZ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | SPRO |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 129.6M |
| IPO Year | 2017 | 2017 |
| Metric | DOGZ | SPRO |
|---|---|---|
| Price | $1.45 | $2.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 300.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,977,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.02 | $0.51 |
| 52 Week High | $34.53 | $3.09 |
| Indicator | DOGZ | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 19.41 | 48.98 |
| Support Level | $1.10 | $2.30 |
| Resistance Level | $1.53 | $2.44 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 37.19 | 61.54 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.